We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA is splitting up responsibilities for reviewing direct-to-consumer (DTC) ads based on the product type because the agency is falling behind in addressing its growing workload, a high-ranking agency official says.